文献速递核素与放射性配体治疗放射性药物与辐射防护

肝肿瘤选择性内放射治疗前定量SPECT/CT评估肺分流分数的前瞻性研究

A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors.
PubMed 文献 · J Nucl Med · 2018-01-25

前瞻性纳入50例拟行选择性内放射治疗(SIRT)的患者,注射99mTc-大颗粒白蛋白(99mTc-MAA)后行平面显像与SPECT/CT。平面显像肺分流分数(LSF)中位数6.8%,SPECT/CT定量中位数1.9%,显著更低(P<0.0001);平面显像下10例LSF≥10%需考虑减量或禁忌,而SPECT/CT仅2例显示明显分流。

要点

  • 50例拟行SIRT患者注射99mTc-MAA后1小时内行SPECT/CT定量评估LSF。
  • 平面显像LSF中位数6.8%(范围3.4%-32.3%),SPECT/CT中位数1.9%(范围0.8%-15.7%),P<0.0001。
  • 平面显像下10例LSF≥10%需考虑减量或禁忌SIRT,SPECT/CT仅2例显示明显分流。

核心结论

  • 定量SPECT/CT显示LSF显著低于平面显像,肺实质所受剂量可能低于传统假设。
  • 基于SPECT/CT所得剂量范围的安全性尚需评估。

研究设计与样本

  • 前瞻性临床队列研究,连续纳入50例拟行SIRT的肝肿瘤患者。
  • 注射99mTc-MAA后1小时内行SPECT/CT γ相机采集,先行肺与肝区前后位平面显像,再行胸腹部SPECT/CT。
  • 对发射数据进行散射、衰减和分辨率恢复校正,在SPECT/CT图像上勾画肺、肝、膀胱及胸腹部其余体部的感兴趣体积,以注射剂量百分比(%ID)计算99mTc-MAA浓度。

主要发现

  • 肝与肺的平均99mTc-MAA摄取合计仅占79 %ID,而其余体部占13.1 %ID。
  • 全部患者平面显像计算的LSF中位数为6.8%(范围3.4%-32.3%),SPECT/CT定量LSF中位数为1.9%(范围0.8%-15.7%),SPECT/CT显著更低(P<0.0001,Wilcoxon检验)。
  • 基于平面显像,50例中10例因LSF计算≥10%需考虑剂量减少甚至SIRT禁忌。
  • SPECT/CT定量显示50例中仅2例存在明显分流。

临床怎么用

  • 作者结论指出定量SPECT/CT显示的LSF显著低于平面显像,肺实质剂量可能低于传统假设。
  • 作者指出基于SPECT/CT所得剂量范围的安全性尚需评估。

局限性

  • 作者指出基于SPECT/CT所得剂量范围的安全性尚需评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The lung shunt fraction (LSF) is estimated using 99mTc-macroaggregated albumin (99mTc-MAA) imaging before selective internal radiotherapy (SIRT) of the liver to reduce the risk of pulmonary irradiation. Generally, planar scans are acquired after injection of 99mTc-MAA into the hepatic artery. However, the validity of this approach is limited by differences in attenuation between liver and lung tissue as well as inaccurate segmentation of the organs. The aim of this study was to evaluate quantitative SPECT/CT for LSF assessment in a prospective clinical cohort. Methods: Fifty consecutive patients intended to undergo SIRT were imaged within 1 h after injection of 99mTc-MAA using a SPECT/CT γ-camera. Planar scans of the lung and liver region were acquired in anterior and posterior views, followed by SPECT/CT scans of the thorax and abdomen. Emission data were corrected for scatter, attenuation, and resolution recovery using dedicated software. To quantify the radioactivity concentration in the lung, liver, urinary bladder and remainder of the thoracoabdominal body, volumes of interest were defined on the SPECT/CT images. 99mTc-MAA concentrations were calculated as percentage injected dose (%ID). Results: Mean 99mTc-MAA uptake in liver and lung accounted for only 79 %ID, whereas 13.1 %ID was present in the remainder of the body. In all patients, LSF as calculated from planar scans accounted for a median of 6.8% (range, 3.4%-32.3%), whereas the SPECT/CT quantitation revealed significantly lower LSF estimates, at a median of 1.9% (range, 0.8%-15.7%) (P < 0.0001, Wilcoxon test). On the basis of planar imaging, dose reduction or even contraindications to SIRT had to be considered in 10 of 50 patients, as their LSF was calculated at 10% or more. In contrast, SPECT/CT quantitation showed substantial shunting in only 2 of the 50 patients. Conclusion: Quantitative SPECT/CT reveals that the LSF is considerably lower than shown on planar imaging. Thus, the resulting dose to the lung parenchyma may be less than conventionally assumed. However, the safety of the SPECT/CT-derived dose range will have to be evaluated.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dittmann H, Kopp D, Kupferschlaeger J, et al. A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors. J Nucl Med. 2018. PMID: 29371406. doi:10.2967/jnumed.117.205203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。